{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:31:56Z","timestamp":1787160716091,"version":"build-2736575974"},"reference-count":31,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:00:00Z","timestamp":1715472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    An intramuscular (IM) suspension of benzathine penicillin G (BPG) has been used as first\u2010line therapy for the treatment of syphilis worldwide since its approval in the 1950s. However, there are limited reports about the pharmacokinetics of BPG. A Phase 1 study was conducted on eight Japanese healthy participants to investigate the pharmacokinetics (samples collected predose to 648 h post\u2010dose) and safety of 2.4 million units of BPG after a single IM injection. Following administration, penicillin G, the active moiety of BPG, was absorbed slowly from the injection site with a median time to C\n                    <jats:sub>max<\/jats:sub>\n                    (t\n                    <jats:sub>max<\/jats:sub>\n                    ) of 48 h post\u2010dose. After the achievement of C\n                    <jats:sub>max<\/jats:sub>\n                    , concentrations of penicillin G declined slowly in a monophasic fashion with a mean apparent terminal half\u2010life of 189 h. Geometric mean AUC\n                    <jats:sub>inf<\/jats:sub>\n                    and C\n                    <jats:sub>max<\/jats:sub>\n                    were 50770 ng\u2022h\/mL and 259 ng\/mL, respectively. Median time (range) above the well\u2010accepted therapeutic concentration (18 ng\/mL) for syphilis treatment was 561 h (439\u2010608 h [18\u201025 days]), which reached and exceeded the necessary duration of 7\u201010 days for syphilis treatment. Two participants were underdosed with residual drug left in the syringe due to the high viscosity of the drug product. Only one (12.5%) participant reported a mild adverse event of nasopharyngitis, which was considered not related to the study treatment. The study results supported BPG approval in Japan as an option for syphilis treatment.\n                  <\/jats:p>","DOI":"10.1002\/jcph.2454","type":"journal-article","created":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T23:39:11Z","timestamp":1715557151000},"page":"1259-1266","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics and Safety of Intramuscular Injectable Benzathine Penicillin G in Japanese Healthy Participants"],"prefix":"10.1002","volume":"64","author":[{"given":"Yinhua","family":"Li","sequence":"first","affiliation":[{"name":"Pfizer R&amp;D  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5490-2606","authenticated-orcid":false,"given":"Akifumi","family":"Okayama","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Hagi","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieko","family":"Muto","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Raber","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Nagashima","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.23562"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.32.1.68"},{"issue":"4","key":"e_1_2_10_4_1","first-page":"507","article-title":"A decade of reorientation in the treatment of venereal syphilis","volume":"10","author":"Idsoe O","year":"1954","journal-title":"Bull World Health Organ"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/bf02014334"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ714"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.13.2271"},{"key":"e_1_2_10_8_1","unstructured":"WHO Guidelines for the Treatment of Treponema pallidum (syphilis). Geneva: World Health Organization;2016. Available from:https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK384904\/"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16946"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010197601040\u201000004"},{"key":"e_1_2_10_11_1","first-page":"6","article-title":"The nature of penicillin, mode of action, and principles of penicillin therapy","volume":"47","year":"1972","journal-title":"Bull World Health Organ"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268819000281"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.NPR.0000790496.90015.74"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.11.010"},{"key":"e_1_2_10_15_1","unstructured":"Diseases NIoI.Summary of syphilis notifications in Japan. Accessed April 2 2024.https:\/\/www.niid.go.jp\/niid\/images\/epi\/syphilis\/2022q4\/syphilis2022q4.pdf"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.3013"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.04.042"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2011.10.003"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040216"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2010.047712"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2305.161936"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000005773"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3999\/jscpt.46.233"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.07.017"},{"key":"e_1_2_10_25_1","unstructured":"Food and Drug Administration Guidance for Industry: Bioanalytical Method Validation.2001."},{"key":"e_1_2_10_26_1","unstructured":"European Medicines Agency Guideline on Bioanalytical Method Validation.2011 EMA\/CHMP\/EWP\/192217\/2009."},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454\u2010200406000\u201000028"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.6.1332"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12014"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025308"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000238397"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02744\u201014"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T01:35:29Z","timestamp":1727400929000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,12]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1002\/jcph.2454"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2454","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,12]]},"assertion":[{"value":"2024-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}